Actively Recruiting
Dose-Finding Study of Oral Paclitaxel Combined with Epirubicin and Cyclophosphamide for Neoadjuvant Treatment of Triple-Negative Breast Cancer in Women Aged 18 to 70
Led by Liu Shu · Updated on 2026-08-04
30
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multicenter, open-label trial to find the maximum tolerated dose and recommended phase 2 dose of oral paclitaxel followed by epirubicin plus cyclophosphamide therapy in women with triple-negative breast cancer. This study focuses on patients aged 18 to 70 with confirmed invasive triple-negative breast cancer. The goal is to identify the best dose levels of oral paclitaxel to use safely in combination with these chemotherapy drugs. Participants receive treatment in three groups with different doses of oral paclitaxel 125, 150, or 175 mgm2. The trial involves four cycles of epirubicin and cyclophosphamide administered intravenously every three weeks, followed by four cycles of oral paclitaxel given twice daily on days 1, 8, and 15 of each three-week cycle. This dose-finding phase is designed to evaluate safety and determine the optimal dosing schedule. During the study, participants are monitored for side effects and treatment response for up to about 30 weeks. Researchers assess the maximum tolerated dose and measure outcomes such as pathological complete response and overall response rate. Safety evaluations include heart function and organ health, with ongoing follow-up to ensure participant well-being throughout the treatment period.
CONDITIONS
Brief Title
Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
Research Team
S
Shu Liu
Y
Yu Ren
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here